MGMT and neoplasm: The total tumor/edema ratio was predictive of non MGMT promotor methylation from DeepBraTumIA (AUC 0.667, 95% CI 0.540–0.794, sensitivity 60.5%, specificity 68.7%, at Youden optimal cutoff 0.449) and Raidionics (AUC 0.687, 95% CI 0.562–0.811, sensitivity 44.7%, specificity 87.5%, at Youden optimal cutoff 0.625) (Table 4).